BioSpace News Archive

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in the diagnostic US-based 64Cu SAR-bisPSMA trial for patients with biochemical recurrence (BCR) of prostate cancer.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today presented its PLACCINE platform technology at the World Vaccine Congress taking place in Washington D.C.

Syndromic multiplex testing is proving itself in the market, with players reporting double-digit growth.

Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-generation small molecule drugs, today announced the appointment of Robert J. Buckley as its Chief People Officer.

Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the first quarter of 2022.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.

Maxwell Biosciences today announced the appointment of Edward Rudnic, Ph.D., as Chief Operating Officer, effective immediately.